Compare Amplitude Inc (AMPL) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplitude Inc vs BioNTech SE - ADR — how do they compare? Amplitude Inc trades at $12.38 (market cap $1.59B), while BioNTech SE - ADR trades at $93.06 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 14.7× Amplitude Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| AMPL | BNTX | |
|---|---|---|
Market Cap | $1.59B | $23.31B |
Sector | Technology | Health |
52-Week High | $12.69 | $119.34 |
52-Week Low | $5.61 | $83.89 |
Enterprise Value | $1.45B | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPL trades at $12.37, up 1.48% today, with a bullish technical signal from moving averages. Revenue grew to $343.21M in 2025, but net losses persist at -$88.54M. Analyst consensus is bullish with a $12.08 price target, supported by enterprise and AI-driven growth initiatives highlighted in recent earnings calls. The stock shows strong institutional buy ratings despite negative profitability metrics.
Outlook remains cautiously optimistic due to revenue growth and AI expansion, but risks include sustained losses, cash flow deficits, and ongoing legal investigations. The stock's valuation at P/S 4.49 may appeal if profitability improves, yet high P/B 11.64 signals premium pricing relative to book value.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
